Phase Space AI

Trade Construction

Stryker [SYK]

Stryker Corporation [SYK] — Trade Construction & Risk Management (Task 5)

investment-memo v1.6.0 · analysis dated 2026-07-28, migrated onto the Criteria framework 2026-07-29 Spot: $346.57 (scan) / $346.60 (Alpaca close in the body) · Archetype COMPOUNDER

This document no longer states a position verdict

Under v1.6.0 the memo scores every Criteria and blocks on none of them. It emits an analysis, not a position. The prior version concluded WATCHLIST — LONG BIAS with a named "binding Criteria"; both are removed. The evidence that produced them is unchanged and retained.

CRITERIA                        TYPE       RESULT
  Quality Criteria              BINDING    PASS (qualified) — robotic-orthopaedic adoption evidenced from
                                                    PubMed and FDA 510(k) records, independent of the company
  Valuation Criteria            BINDING    FAIL   — implied path requires 15.1% revenue CAGR vs 10.8%
                                                    demonstrated.  MARGIN -4.3pp
  Liquidity Criteria            BINDING    PASS   — mega-cap; options chain also genuinely usable here
  Catalyst Criteria             MEASURED   PASS   — Q2-2026 results 2026-07-30, company-confirmed
  Momentum Criteria             MEASURED   12-1 -17.5%, 19.5th cross-sectional percentile (quintile 1).
                                           ENTRY TIMING ONLY. It does not and cannot block this name.
  Peer Spread Criteria          MEASURED   PASS   — named peer ZBH/MDT; SYK at a 9.3% premium to an 18.97x
                                                    peer median, and at the 9th percentile of its own history
  Downside Criteria             MEASURED   PASS   — permanent-loss case and cause named, s.4
  Short Mechanism Criteria      MEASURED   FAIL   — no decelerating-growth + exhausted-margin configuration
  Consensus Criteria            MEASURED   PASS   — house +1.0% to +2.2% vs Street; inside dispersion on 3 of
                                                    4 lines. Reported; blocks nothing.

VALUATION, TWO HORIZONS (both mandatory)
  Implied-path test (5y reverse DCF):  price requires 15.1% revenue CAGR
                                       demonstrated 10.8%   MARGIN -4.3pp
                                       exit multiple 22.7x EV/EBIT, basis GROWTH_MATCHED (n=31)
                                       implied compression from 29.3x today: -22.5%
                                       breakeven exit multiple: 27.5x
  12-month target (own P/S history):   base $390 (+12.5%), band $317 (-8.5%) to $403 (+16.4%)

---

0. Portfolio context — the book was read first

portfolio_book.json, as of 2026-07-27: positions = empty, book 100% cash. Watchlist: MU, ISRG, NBIS, SMR, AAOI, SNDK, GH, NTRA, TXG, TWST, NET, MSFT, GOOGL, AMZN, META, COO. One SHORT recommendation (CIEN) recorded but not executed.

Relevant limits: max single-name weight 5.0%; max sector concentration 25%; max pairwise correlation without disclosure 0.60; cash hurdle 4.7%; drawdown ladder −5% review / −10% de-gross / −15% stop.

Correlation check. SYK vs the correlated watchlist names, 252-day daily log returns (Alpaca SIP):

No correlation breach. The healthcare cluster (ISRG, GH, NTRA, TXG, TWST, COO + SYK) is now seven of sixteen watchlist names. If several convert together, the 25% sector limit binds before any single-name limit does. Flagged for the book.

---

1. Four conclusions kept separate

---

2. THE CRITERIA

Quality Criteria — Causal mechanism (improving fundamentals) · PASS, QUALIFIED

Named mechanism, for a long:

1. Robotic-orthopaedics adoption is compounding, and it is evidenced, not hypothesised. PubMed publications on robotic-assisted TKA: 2 (2016) → 46 (2022) → 154 (2025), still accelerating. Orthopaedic surgeons adopt on published evidence and the evidence base is inflecting. Independent of any company statement.
2. The regulatory cadence has tripled. Four Mako 510(k) clearances in the 21 months to Feb-2026 (K241011, K241517 Mako Spine, K242373 Mako Shoulder 1.0, K243751 Hip 5.0, K250608 Knee 3.0, K260222) against three in the prior five years. Both expansion vectors are already cleared; the Criteria is commercialisation.
3. Cyber-deferred revenue is recoverable. ~$440m (my derivation from the filed organic bridge) did not ship in Q1-2026. Orthopaedic implant demand is scheduled, not impulse; a postponed knee is performed later. Management has stated in an Item 1.05 8-K/A that full-year guidance is unaffected.

Quantitative corroboration (the required standard) — genuinely split, and stated as such:

Verdict: PASS, but qualified. The mechanism is real and evidenced from independent corpora. The scorecard does not unanimously corroborate it — it splits along a clean fault line: the operating quality metrics support a long, the capital-allocation metrics fight it. Per the Criteria's own standard, a long whose scorecard is mixed needs correspondingly stronger narrative evidence, and the PubMed/FDA corroboration supplies it. This is a pass, not a comfortable one.

---

the dissolved variant-vs-consensus test (old Gate 2) — Variant vs consensus · FAIL ← THE BINDING CRITERIA

the dissolved variant-vs-consensus test (old Gate 2A) — Estimate variant · FAIL

The metric the Quality Criteria mechanism moves is FY2026-27 organic revenue and adjusted EPS.

(Alpha Vantage EARNINGS_ESTIMATES, 26 analysts, pulled and cached 2026-07-28.)

On three of four lines the house view sits inside the range of published estimates. On the other two it clears the high by 0.6–0.7%. A 1–2% gap against a 26-analyst consensus with a ±1.9% published range is not a variant view; it is agreement.

The strongest available 2A argument, and why it still fails. Consensus FY2026 revenue of $27,271m requires Q2-Q4 organic of ~9.4% against a delivered Q2-Q4 2025 run rate of 10.2% — i.e. the Street embeds essentially no recovery of the cyber-deferred ~$440m. Management has stated the opposite. So the house is arguably taking the company's side against a sceptical Street.

That is a real observation and it is not a variant view, for three reasons: 1. Siding with guidance against the Street is the weakest possible form of variant. Everyone can read the 8-K/A. There is no informational asymmetry; there is a difference of opinion about whether to believe management, which 28 analysts have already had. 2. The magnitude is inside dispersion. Full recovery instead of half takes FY2026 revenue to $28,011m — the Bull case, weighted 25%, not the base. 3. It is resolved in two days. The Q2-2026 print (2026-07-30) reveals the answer before any position could be sized. A variant that expires in 48 hours is a coin flip, not an edge.

the dissolved duration-variant test (old Gate 2B) — Duration / optionality variant · FAIL, on leg 4

The candidate is Mako's expansion into shoulder, spine and the Mako 4 platform. All four legs are required:

the dissolved duration-variant test (old Gate 2B) fails on leg 4, and this failure is not the B5 borderline case. B5 in CALIBRATION_WATCH.md records that leg 4 may be near-unfalsifiable, because proving a quantified gap requires line-item consensus that does not exist publicly. That concern is legitimate in general. It does not apply here. The problem is not that consensus's treatment of Mako is unobservable — it is that consensus's treatment of Mako is the entire sell-side thesis on this stock. There is no plausible world in which 28 analysts covering the world's largest orthopaedics company have not modelled its robotics franchise.

Also worth recording against the expansion narrative specifically: "robotic shoulder arthroplasty" returns ONE PubMed publication, ever, and it appeared in 2026 — twenty months after FDA clearance, against 562 papers for robotic TKA. And zero Stryker-sponsored trials of robotic shoulder or spine exist across all 101 registered studies. The expansion vectors are cleared but pre-evidence, which argues they are further out than the narrative implies, not nearer.

SUPERSEDED (2026-07-29). The original read: "Gate 2 FAILS. Under the framework this alone forces the decision to Watchlist regardless of every other gate's result." The variant-vs-consensus test is dissolved, not renamed — no variant versus consensus is required by v1.6.0, and with it goes the contrarian-only trap and the Path B contradiction. The finding above (the house is inside consensus dispersion) is retained as Consensus Criteria — MEASURED, reported, blocking nothing.

---

Catalyst Criteria — MEASURED · dated event exists · PASS

The catalyst exists and is unusually clean. Q2-2026 results, 2026-07-30, 4:05pm ET, company-confirmed — two days from today. It resolves exactly the point at issue: did the cyber-deferred revenue come back?

Consensus Q2-2026: revenue $6.56bn (+8.9% YoY), adjusted EPS $3.46 (+10.5%). The specific test:

Also watch: whether the FY2026 organic guide of 8.0–9.5% is raised (Stryker raised at Q1 in both FY2024 and FY2025 and merely maintained in FY2026 — see Exhibit 19), and whether reported Orthopaedics growth jumps ~6–8pp purely because the US spine divestiture anniversaries this quarter. That jump is mechanical and means nothing.

Timing note (not a failure). A catalyst 48 hours away, with an option-implied move of ±7.9% to the August expiry, is not something a position can be built into. Under v1.6.0 that is an entry-timing observation consumed alongside the Momentum Criteria; the Catalyst Criteria itself is MEASURED and asks only whether a dated event exists that would confirm or refute the implied path. It does. The usable statement is narrower: a two-day binary is not an entry window. That is a timing observation, not a reason to own or not own the name.

The thesis-resolving event proper is FY2027 guidance at the Q4-2026 print, ~2027-01-28.

---

Valuation Criteria — implied path · FAIL, margin −4.3pp (BINDING for a long-only absolute-return book)

Fully rewritten. The prior version tested a scenario-weighted E[R] of +9.55% against a 4.7% cash hurdle and ranged the result over bear-case probabilities. Both halves are retired. Full working in SYK_Valuation.md §0.1; inputs from reports/scan/SYK_analysis.json, not recomputed.

Sensitivity over the exit multiple (never over probabilities):

Breakeven is a 27.5x exit multiple against 29.3x today — a 6% compression over five years rather than the 22% the growth-matched anchor implies. Of the four names migrated in this batch, SYK is the closest to passing.

Terminal-margin note. SYK_analysis.json carries no terminal_margin field; the published required CAGR inverts to a flat 20.0% applied universe-wide (the hardcoded 0.20 that coverage_scan.py records as a since-fixed defect). Using SYK's own 19.5% operating margin gives required 15.7%, margin −4.9pp — slightly worse. Disclosed, not silently applied.

Liquidity Criteria — Implementation feasibility · PASS — the cleanest in this coverage

The options market read — and this is a first for this coverage.

(Alpaca options snapshots, quotes as of 2026-07-28 19:59:53Z.)

August ATM implied vol of 36–41% sits AT or BELOW 30-day realised vol of 41.3%. Every prior name in this coverage failed the options test because implied sat 15–30 vol points above realised (NBIS 139-164% vs 105-137%; CIEN 89-100% vs 68-79%). SYK is the first name where options are not systematically overpriced — the variance risk premium is compressed here, plausibly because the market has not fully re-marked vol after the March disruption.

That makes an options expression feasible. It does not make it warranted — the dissolved variant-vs-consensus test (old Gate 2) has already failed, and a defined-risk structure into a 48-hour binary is still a bet on a coin flip with a small edge in the pricing. No options trade is recommended here. The pricing is documented so that, if a book chooses to act, the vehicle decision starts from real numbers rather than being re-derived.

Liquidity Criteria PASSES. Note explicitly, per the CIEN lesson: the vehicle question and the position question are separate. Here both the equity and the options market are workable. The block is upstream, at the dissolved variant-vs-consensus test (old Gate 2).

---

Momentum Criteria — MEASURED. Entry timing only. It cannot veto this name.

The type discipline is the point of this section. Momentum was a blocking gate, was demoted to timing, and is the change most likely to be silently reversed under pressure. Any earlier language here about "fighting the tape", initiating "against" momentum, or dropping a conviction tier because of it is deleted: momentum governs when to enter a position the thesis already justifies, never whether to own it.

Assessed cross-sectionally, not by absolute rules such as "above the 200-day" — the absolute-rule form is what gave a MEASURED quantity blocking power in the first place.

Read as timing: SYK is a bottom-quintile 12-month relative-momentum name (19.5th percentile) whose intermediate and short-horizon trend has turned up — price above both the 50- and 200-day, RSI-14 at 59.4, 23% off the 52-week low. That combination describes a favourable entry window in a name with poor trailing momentum, which is precisely the configuration the old blocking rule handled worst.

CORRECTION (2026-07-29) — 12-1 momentum. The scan reports −17.5%; this document previously reported −16.9%, and an independent recomputation on this project's Alpaca bars gives −14.4%. The three differ by lookback convention (skip-month placement and end date). The scan's figure is used because it is the one the cross-sectional percentile was computed against, and the percentile is what the framework consumes. The spread is noted, not averaged away.

On calibration item B1. B1 asks whether momentum wrongly blocks a cheap, high-quality compounder that has fallen. SYK is the clearest instance of that configuration in coverage — 9th percentile of its own five-year P/S history, bottom-quintile 12-1 momentum. Under v1.6.0 the question is closed by construction, not by outcome: Momentum Criteria is MEASURED and has no blocking power to misuse.

---

3. CRITERIA SUMMARY (replaces "INVESTMENT DECISION")

The position verdict has been removed, not softened. The prior version of this section read WATCHLIST — LONG BIAS, named a binding Criteria, and set a position size of 0.0%. v1.6.0 outputs an analysis, not a position. Whether this analysis justifies capital is a question about a particular book, and two books answer it differently.

What the old section got right, kept. The framework's founding error (NET, reversed 2026-07-26) was reasoning from a valuation gap to a directional call. SYK is 13.7% below its own five-year NTM multiple and at the 9th percentile of its own five-year P/S history, its factor quality is good — and none of that on its own constitutes knowing something. That remains true and is worth stating.

What the old section got wrong, removed. It converted "no variant versus consensus" into a forced classification. v1.6.0 dissolves that test: no variant versus consensus is required. The Consensus Criteria records the gap and blocks nothing.

---

4. Conversion triggers, sizing, and pre-authorised mechanics

Route A — Price (valuation-driven, requires no new information)

Route B — Variant (price-independent — the route that would actually fix the dissolved variant-vs-consensus test (old Gate 2))

the dissolved variant-vs-consensus test (old Gate 2) becomes satisfiable if any two of the following occur:

1. Stryker discloses a Mako-specific operating metric — installed base, quarterly placements, procedures, or an Ortho Tech revenue line — for the first time. This would restore the inference the 2026Q1 reorganisation destroyed and create a metric on which a variant is possible. First checkable: Q2-2026, 2026-07-30.
2. The Mako Spine full US commercial launch lands on schedule (guided H2-2026) and robotic-spine publications exceed 80 in calendar 2026 (2025: 61; 2026 run-rate: 30 through July). This would evidence that the second vector is converting from clearance to adoption.
3. Consensus FY2028 revenue is revised up by more than 3% without a guidance raise or M&A — observable evidence that the Street is re-rating the runway, i.e. that duration was previously under-modelled. Check quarterly against the cached Alpha Vantage baseline.
4. Robotic-shoulder publications reach 10+ in a calendar year. From one paper ever, this would be the inflection that makes the shoulder vector real rather than notional.

Route C — Post-print re-underwrite (dated, mandatory)

2026-07-30, after the close. This memo is deliberately written 48 hours before the event that resolves its central uncertainty. Re-run Task 8 on the print. Specifically: - Compute the PEAD check: Q2 adjusted EPS surprise versus the $3.46 consensus, plus the 30-day revision direction. - If organic growth prints > 12.5% and the FY2026 guide is raised, the Bull case is confirmed, Base moves toward $410 and Route A's trigger should be lifted toward $330. - If organic growth prints < 9.0%, the Bear case is live — a Downside Criteria trigger with a named cause, not a verdict: cut the Route A reference level to $270.

Downside Criteria (MEASURED) — permanent-impairment case and named causes

• FY2026 organic guidance cut below 8.0% at any print → Quality Criteria mechanism materially impaired.
• Two consecutive quarters of organic growth below 8.0% ex-cyber → the 16-quarter streak is over; the entire Quality Criteria mechanism weakens.
• A second material cybersecurity incident, or any auditor commentary on internal controls arising from the first → Quality Criteria mechanism materially impaired. The Q1-2026 10-Q already warns that manual workarounds "may increase the risk of errors, delays or data integrity issues (including with respect to… processes supporting financial and operational reporting)."
• A goodwill impairment on Inari or any acquisition completed since 2022.
• Adjusted-vs-GAAP EPS gap exceeding 70% of GAAP in any full year.
• Announcement of an acquisition above $6bn funded with equity.

Vehicle: why no options trade is recommended

The chain is priced and documented for future use. A defined-risk structure that would be the starting point on conversion:

Priced and explicitly rejected today, for three reasons: (i) the dissolved variant-vs-consensus test (old Gate 2) has failed, so no directional expression is warranted; (ii) it requires a +5.4% move merely to break even into a 48-hour binary; (iii) if the analysis converts on Route A at $305, the correct vehicle is outright equity — a long-dated compounder thesis should not be expressed with a decaying instrument. Nothing is logged to trade_recommendations.jsonl for SYK.

(One genuinely notable data point for the ledger's own calibration: this is the first name in fifteen where implied vol did NOT sit far above realised. If a pattern emerges that Liquidity Criteria has been rejecting options expressions on names where vol was mispriced rather than on names where the thesis was wrong — calibration item S2 — SYK is the control observation.)